Indaptus Therapeutics (NASDAQ:INDP) Stock Price Up 5.7% – Here’s What Happened

Indaptus Therapeutics, Inc. (NASDAQ:INDP)’s stock price shot up 5.7% on Thursday. The company traded as high as $4.04 and last traded at $3.9850. 179,677 shares were traded during mid-day trading, a decline of 72% from the average session volume of 630,641 shares. The stock had previously closed at $3.77.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on INDP. Wall Street Zen raised shares of Indaptus Therapeutics to a “hold” rating in a research report on Saturday, June 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has a consensus rating of “Sell”.

Indaptus Therapeutics Stock Performance

The stock has a fifty day simple moving average of $1.94 and a 200 day simple moving average of $2.25. The firm has a market cap of $512.97 million, a P/E ratio of -0.61 and a beta of 1.17.

Indaptus Therapeutics (NASDAQ:INDP) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.57) by $1.55.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer and other serious diseases. The company’s approach is designed to activate the body’s innate and adaptive immune systems to generate a broad, potentially durable therapeutic response.

Indaptus’s lead platform, Decoy20, is based on an engineered formulation of inactivated bacteria intended to stimulate immune cells without causing an active infection. The company has been evaluating Decoy20 as a treatment for advanced solid tumors, including in combination with other cancer therapies.